Apnimed prices IPO at $16 per share, raising $192 million

Apnimed, a late-stage drug developer focused on sleep apnea and backed by Shionogi, has raised $192 million through an upsized US initial public offering. The IPO was priced at $16 per share, reaching the top of the marketed range. This financial milestone allows the biotech company to secure significant capital to further its research and development goals. The offering marks a critical transition for Apnimed as it enters the public equity markets to advance its pipeline.